Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
18.03
-0.75 (-3.99%)
At close: Aug 28, 2026, 4:00 PM EDT
18.10
+0.07 (0.39%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Janux Therapeutics Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Janux Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $36.24. The average 1-year stock price forecast is 101.00% higher than the current stock price, while the lowest is $14 (-22.35%) and the highest is $75 (+315.97%).
Price Target: $36.24 (+101.00%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Janux Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 13 | 13 | 13 | 14 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 18 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Upgrades $23 | Buy | Upgrades | $23 | +27.57% | Aug 24, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 13, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $35 | Buy | Maintains | $35 | +94.12% | Aug 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $45 | Buy | Maintains | $45 | +149.58% | Aug 10, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $60 | Buy | Maintains | $60 | +232.78% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
29.46M
from 10.00M
Increased by 194.58%
Revenue Next Year
8.09M
from 29.46M
Decreased by -72.52%
EPS This Year
-1.73
from -1.83
EPS Next Year
-2.62
from -1.73
EPS and Forward PE are based on non-GAAP adjusted numbers.